Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.65 |
| ▸ | RECQL | P46063 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 2/20 | 0.45 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.38 |
| ▸ | ADCY2 | Q08462 | 3/20 | 0.38 |
| ▸ | HCAR1 | Q9BXC0 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3497134 | 0.79 | L3MBTL1 (1.00) | L3MBTL1GAAMEN1KMT2AMAPT | |
| SCHEMBL3196483 | 0.78 | GAA (0.48) | RECQLGAAALOX15MEN1KMT2A | |
| SCHEMBL3189406 | 0.77 | L3MBTL1 (0.55) | L3MBTL1KDM4E | |
| SCHEMBL3189399 | 0.77 | L3MBTL1 (0.55) | L3MBTL1KDM4E | |
| SCHEMBL3189141 | 0.74 | L3MBTL1 (0.57) | L3MBTL1GAAMEN1KMT2AKDM4E | |
| SCHEMBL3189157 | 0.74 | L3MBTL1 (0.57) | L3MBTL1GAAMEN1KMT2AKDM4E | |
| SCHEMBL3493993 | 0.74 | L3MBTL1 (0.52) | L3MBTL1MEN1KMT2AMAPT | |
| SCHEMBL3173961 | 0.74 | L3MBTL1 (0.60) | L3MBTL1RECQLGAAMEN1KMT2A | |
| SCHEMBL3173943 | 0.74 | L3MBTL1 (0.60) | L3MBTL1RECQLGAAMEN1KMT2A | |
| SCHEMBL3194899 | 0.73 | MEN1 (0.50) | L3MBTL1RECQLGAAALOX15MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100137294-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR CONTROLLING INVERTEBRATE PESTS | GENETIC TECHNOLOGIES LIMITED (AU) | 2010-06-03 | — | — | US | claimed |
| US-20100137294-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR CONTROLLING INVERTEBRATE PESTS | GENETIC TECHNOLOGIES LIMITED (AU) | 2010-06-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100137294-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR CONTROLLING INVERTEBRATE PESTS | PPP1R10, TASP1, PPP5C | L3MBTL1 598/4885RECQL 4531/4885GAA 3610/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.